Barclays »

Arrivent Biopharma shares owned by Barclays

Quarter-by-quarter ownership of Arrivent Biopharma (AVBP) shares owned by Barclays from 13F filings

Historical chart of Barclays investment in Arrivent Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Arrivent Biopharma held by Barclays consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arrivent Biopharma by Barclays

Quarter filed Position value Share count Share price at filing
2024-06-30 $63k 3.4k 18.58
2024-03-31 $254k 14k 17.87

More positions owned by Barclays

SPDR S&ampP 500 ETF TR Fund (SPY)
Invesco Qqq Tr Fund (QQQ)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Ishares Tr Fund (IWM)
Amazon (AMZN)
Alphabet Inc Class A cs (GOOGL)
Facebook Inc cl a (META)
Tesla Opt Call Option (TSLA)
Ishares Tr Fund (HYG)
Broadcom (AVGO)
Berkshire Hathaway (BRK.B)
Texas Instruments Incorporated (TXN)
Alphabet Inc Class C cs (GOOG)

View all positions for Barclays

Top funds holding Arrivent Biopharma

Hillhouse Capital Advisors
OrbiMed Advisors
Octagon Capital Advisors
Suvretta Capital Management
Sofinnova Ventures
Novo A/S
Sc China Holding
BlackRock
Vanguard Group
Cormorant Asset Management
Perceptive Advisors
Geode Capital Management
State Street Corporation
Woodline Partners
Charles Schwab Investment Management

View all funds holding Arrivent Biopharma